BI 894416|CAS 1810059-82-5|DC Chemicals

Cas No.:	1810059-82-5
Chemical Name:	BI 894416
SMILES:	O=C1NC[C@H]([C@H](OC2=NC(C3=CN(C(C)(C)C)N=C3)=CC4=NN(C)C=C24)C)C1
Formula:	C₂₀H₂₆N₆O₂
M.Wt:	382.47

Cat. No.	Product name	Field of application
DC48364	Sovleplenib	Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases.
DC48025	Cevidoplenib dimesylate	Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
DC40848	SRX3207	SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.
DC28254	Lanraplenib monosuccinate	Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
DC74427	RDN2150	RDN2150 is a potent, selective and covalent ZAP-70 inhibitor with IC50 of 14.6 nM, shows no significant activity against Syk, covalently binds to the C346 residue of ZAP-70.
DC74426	RDN009	RDN009 (RDN-009) is a potent, selective, and covalent ZAP-70 kinase inhibitor with IC50 of 55 nM.
DC74425	MTX-216	MTX-216 (MTX216) is a dual PI3K/EGFR inhibitor that blocks neurofibromin 1 loss of function (NF1LoF) melanoma cell growth in vitro and in vivo, suppresses the activity of SYK kinase with IC50 of 281 nM.
DC74424	MRL-SYKi	MRL-SYKi is a potent, selective inhibitor of Syk (Spleen tyrosine kinase) with IC50 of <100 nM, also potently inhibits ZAP70 (24 nM in vitro).
DC74423	BI 894416	BI 894416 is a novel potent and selective SYK inhibitor developed to treat severe asthma.
DC74422	BI 1342561	BI 1342561 is a novel potent and selective SYK inhibitor developed to treat severe asthma.